<DOC>
	<DOC>NCT01131091</DOC>
	<brief_summary>This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each.)</brief_summary>
	<brief_title>A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403</brief_title>
	<detailed_description>This is a Phase 1, multicenter, open label, single dose study. A total of 30 subjects are planned (5 groups of 6 subjects each) as follows: Group A: Subjects with ESRD who are receiving hemodialysis treatment Group B: Subjects with severe renal impairment Group C: Subjects with moderate renal impairment Group D: Subjects with mild renal impairment Group E: Healthy subjects</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subject is an adult male or female aged 18 to 79 years, inclusive. All female subjects (that are not 2 years postmenopausal with a documented serum follicle stimulating hormone level &gt;35 mIU/mL) must have a negative serum pregnancy test at Screening and upon Check in to the study clinic. Subject provides written informed consent before any studyspecific evaluation is performed. Subject is able and willing to comply with the protocol and study procedures. Subject has a BMI &gt;37 kg/m2. Subject has taken any prescribed systemic or topical medication Subject has donated more than 450 mL of blood within 30 days before the start of dosing. Subject has received an investigational drug within 30 days before dosing. Subject has had any surgery of the gastrointestinal tract likely to affect drug absorption. Subject has had a clinically significant illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>